drugset

drugset / Trial / NCT01154335

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

NCT01154335 ↗

Phase 1 Completed 18 enrolled SCRI Development Innovations, LLC Novartis Pharmaceuticals · collab OSI Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.

Timeline

Start: 2010-07
Primary completion: 2013-05
Completion: 2013-05

Publications

Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C, Infante JR, Barton J, Burris HA. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs. 2015 Feb;33(1):187-93. doi: 10.1007/s10637-014-0177-3. Epub 2014 Oct 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	5 mg	—
Subject	Everolimus	Small molecule	10 mg	—
Subject	linsitinib	Small molecule	50 mg	—
Subject	linsitinib	Small molecule	100 mg	—

Indications